SecBot SecBot

CTSO

Cytosorbents Corp
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001175151 Healthcare & Medical Devices
$4.85 +0.38 (+8.50%)
Oct 27 4:00 PM ET · prev $4.47
Market cap
$16.6M
Nano cap
Consensus
Sell
0% Buy or better · 6 analysts
Median target
$47.50
+879% · range $15.00–80.00
Next earnings
Nov 3
in 7 days · EPS est. −$0.90
1 year
−71.0%
from $16.72 · Oct 28
30 days
+20.6%
from $4.02
52-week range
$3.06–16.74
−71% from high · low Oct 15
Avg volume 20D
69.3K
Oct 16 spike 678.4K
Short interest
114.4K
≈3.6% of shares · −7.7%
Days to cover
10.3
at average volume
Insider net
+$269.3K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 3, 2026
Strongest MIXED CytoSorbents announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $269.3K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • AnalystsBEARISH

    0 of 6 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.700 → −$0.900 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −7.7% to 114.4K shares. 10.3 days to cover, ≈3.6% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
LPL Financial LLCDOUBLED50,119$18.7K
HRT FINANCIAL LPDOUBLED32,125$12.0K
GOLDMAN SACHS GROUP INCTRIM15,338$5.7K
BNP PARIBAS FINANCIAL MARKETSNEAR_EXIT3$1.00
Rockefeller Capital Management L.P.TRIM1,861$1.1K
WELLS FARGO & COMPANY/MNTRIM250$142.00
RENAISSANCE TECHNOLOGIES LLCTRIM100,120$64.0K
GOLDMAN SACHS GROUP INCTRIM35,952$23.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold3Sell1Strong Sell2
12-month targets · 2 analysts

Price is below the lowest target. Median implies +879%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026WBB Securities
INITIATE
INITIATESpeculative Buy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
CTSO Q3 2026 Earnings After Market Close — 2026-11-03
Recent
Oct 16, 2026
Trading halt
Halt Resumed: CTSO — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-16T18:22:43.000Z | Resumed 2026-10-16T18:27:43.000Z
Oct 16, 2026
Trading halt
Trading Halt: CTSO — LUDP (Volatility Trading Pause)
Cytosorbents Corp Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Oct 16, 2026
Trading halt
Halt Resumed: CTSO — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-16T18:12:09.000Z | Resumed 2026-10-16T18:17:09.000Z
Oct 16, 2026
Trading halt
Trading Halt: CTSO — LUDP (Volatility Trading Pause)
Cytosorbents Corp Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Oct 16, 2026
Trading halt
Halt Resumed: CTSO — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-16T18:06:48.000Z | Resumed 2026-10-16T18:11:48.000Z

Insider ledger

Form 4
$269.3K
bought · 4 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 15, 2026
Chan Phillip P.
Chief Executive Officer
BUY$22.6K
Sep 15, 2026
Sobel Alan D.
Director
BUY$3.0K
Sep 15, 2026
Sobel Alan D.
Director
BUY$11.6K
Sep 15, 2026
Sobel Alan D.
Director
BUY$601.00
Sep 14, 2026
Capponi Vincent
President and COO
BUY$10.9K
Sep 14, 2026
Capponi Vincent
President and COO
BUY$1.6K
Sep 4, 2026
Chan Phillip P.
Chief Executive Officer
BUY$70.0K
Jun 15, 2026
Chan Phillip P.
Chief Executive Officer
BUY$4.4K

Earnings setup

Estimates
Nov 3
reports in 7 days
−$0.90
EPS estimate, this quarter
−29%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.90-$1.00–-$0.80-28.6%$9.9M
Next Q-$0.70-$0.80–-$0.60-40.0%$10.5M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
114,402
shares short
-7.7%
vs prior settlement
10.3
days to cover
≈3.6%
of shares outstanding
Trading halts
Oct 16, 2026Volatility PauseResumed
Oct 16, 2026Volatility PauseResumed
Oct 16, 2026Volatility PauseResumed
Oct 1, 2026Volatility PauseResumed
Sep 4, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Trading halt
Halt Resumed: CTSO — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-16T18:22:43.000Z | Resumed 2026-10-16T18:27:43.000Z
Sep 23, 2026 SEC
CytoSorbents announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share…
8-K — Impact 5/10
Sep 15, 2026 Insider
Chan Phillip P. bought 3,774 shares
Chief Executive Officer @ $6.00 ($22.6K)
Sep 15, 2026 Insider
Sobel Alan D. bought 500 shares
Director @ $6.05 ($3.0K)
Sep 15, 2026 Insider
Sobel Alan D. bought 1,900 shares
Director @ $6.12 ($11.6K)
Aug 6, 2026 SEC
CytoSorbents reported Q2 2026 revenue of $9.6M (flat YoY) and a GAAP net loss of $0.07/share, missing the consensus…
PRESS-RELEASE — Impact 6/10
Jun 30, 2026 Inst.
LPL Financial LLC — DOUBLED
50,119 shares ($18.7K)
Jun 30, 2026 Inst.
HRT FINANCIAL LP — DOUBLED
32,125 shares ($12.0K)

SecBot reports

6 filings · 1 bullish · 2 bearish · 1 mixed · 2 neutral
All CTSO filing & press-release reports (6)